Berlin, Germany – November 11–13, 2025 — Hzymes, a leading global supplier of mRNA raw materials, quality control reagents, and mRNA CRO services, will exhibit at the 13th International mRNA Health Conference 2025, taking place at the InterContinental Berlin, Germany. Visitors can find Hzymes at Booth No. 2 to explore its end-to-end mRNA synthesis solutions, spanning enzyme raw materials, QC kits, and contract research services.

Empowering the Future of mRNA Therapeutics

As a professional supplier of mRNA synthesis reagents and custom mRNA development services, Hzymes delivers high-performance products that support vaccine manufacturing, gene therapy, and RNA-based drug research. With deep expertise in in vitro transcription (IVT) and mRNA capping technologies, Hzymes provides comprehensive solutions from research to production scale.

mRNA Enzymes and Substrates: Driving High-Yield IVT Reactions

At the core of mRNA manufacturing lies enzymatic precision. Hzymes offers a complete portfolio of mRNA enzymes and substrates optimized for high yield, purity, and stability in in vitro transcription workflows.

Key highlights include:

• T7 RNA Polymerase (Mutant) and Hi-yield T7 In Vitro Transcription Reagent, enabling robust and scalable mRNA synthesis.
• DNase I, RNase Inhibitor, and Inorganic Pyrophosphatase for high-purity transcription.
• Vaccinia Capping Enzyme, mRNA Cap 2'-O-Methyltransferase, and Cap Analogues to ensure efficient and accurate mRNA capping.
• NTPs and Modified NTPs for enhanced mRNA translation efficiency and stability.

From BsaI/BspQI restriction enzymes to T4 RNA Ligase and RNase R, Hzymes supports every stage of mRNA template preparation and circular RNA synthesis.

Ready-to-Use mRNA and saRNA Solutions for Research and Development

To accelerate innovation, Hzymes provides a wide range of synthetic mRNA, saRNA, and circRNA products ready for research use:

• Cas9 mRNA, eGFP mRNA, Fluc mRNA — for transfection and gene editing applications.
• COVID-19 Spike and RBD mRNA, Human EPO mRNA — for vaccine and therapeutic protein studies.
• Self-amplifying RNA (saRNA) and circular RNA (circRNA) templates — offering extended expression duration and enhanced stability.

Each mRNA product is synthesized under strict quality standards, ensuring high purity, low immunogenicity, and excellent reproducibility.

Comprehensive mRNA QC Kits for Quality and Compliance

Ensuring consistency and regulatory compliance is critical in mRNA drug development. Hzymes offers a full suite of mRNA QC kits covering all stages of production — from dsRNA detection to endotoxin quantification.

Flagship QC products include:

• dsRNA ELISA Kit and RIG-I dsRNA Quantification Kit for immunogenic dsRNA monitoring.
• Capping Efficiency Detection Kit, DNase/RNase Assay Kit (Fluorescence), and T7 RNA Polymerase ELISA Kit for enzyme performance verification.
• Sample Preparation Kits, RNA Ladder 6000, and Fast LNP (in vivo Delivery System) to streamline testing workflows.
• Recombinant Factor C Endotoxin Detection Kit to ensure biosafety for in vivo applications.

With high sensitivity, GMP compatibility, and fast turnaround, Hzymes’ QC portfolio empowers researchers to meet the rigorous quality standards of mRNA manufacturing.

mRNA CRO Services: From Concept to Clinical Readiness

Hzymes also provides comprehensive mRNA CRO services, supporting clients across the entire R&D pipeline — from proof of concept studies to process development and QC validation.

Core services include:

• mRNA Antigen and Template Synthesis
• mRNA Process Development and Optimization
• Plasmid Synthesis and Purification
• mRNA QC and Analytical Services
• Custom CRO Project Support for vaccines, therapeutics, and diagnostic reagents

With advanced production platforms and an experienced scientific team, Hzymes partners with global biotech innovators to accelerate mRNA drug discovery and manufacturing.

Meet Hzymes at Booth No. 2, Berlin

During the 13th International mRNA Health Conference 2025, Hzymes invites scientists, manufacturers, and industry partners to explore collaborative opportunities in mRNA technology and innovation. Attendees can experience Hzymes’ integrated enzyme-to-mRNA platform, designed to simplify workflows and scale biomanufacturing with confidence.

Visit Hzymes at Booth No. 2 to learn how the company is advancing the future of mRNA synthesis and QC innovation.

About Hzymes

Founded in 2015, Hzymes is a high-tech enterprise dedicated to the R&D, production, and application of specialty enzymes and reagents for in vitro diagnostics, molecular biology, and biopharmaceutical manufacturing.

With a commitment to enzyme innovation and bioprocess excellence, Hzymes provides end-to-end solutions for mRNA synthesis, quality control, and CRO services, empowering the next generation of RNA-based medicines and vaccines.